Howard Fillit, MD: Aducanumab Findings Lead the Way in Dementia
May 20th 2020The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the landmark findings from Biogen on its agent aducanumab and the impact the trial might have on the future.
Analysis Suggests No Link Between OSA and Postoperative Delirium
May 20th 2020Contrary to prior literature, a new single-center analysis suggests that obstructive sleep apnea is not associated with delirium in those who were postoperatively admitted to the ICU, though PAP may reduce delirium in this patient population.
ADDF Diagnostic Accelerator Initiative Invests In Digital Memory Impairment Projects
May 17th 2020The Alzheimer’s Drug Discovery Foundation made 5 new investments through its Diagnostics Accelerator initiative, through which it has $50 million in commitments from leading scientific philanthropists such as Leonard A. Lauder, Bill Gates, Jeff Bezos, and MacKenzie Bezos.